This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: G23.0 | Special Copayment Reduction: V257 | Coverage period: 5 years |
| B. Synonyms | Hallervorden-Spatz disease, pigmentary pallidal degeneration, pantothenate kinase-associated neurodegeneration, PKAN, NBIA type I |
| C. Adult onset | Low likelihood of first onset in adulthood — the classic form begins in childhood (3–10 years); the atypical form may begin in adolescence to adulthood |
| 1. History | Described by Hallervorden and Spatz in 1922; renamed PKAN after identification of the causative gene PANK2 in 2001 |
| 2. Causes | PANK2 gene mutations cause pantothenate kinase 2 deficiency → impaired coenzyme A synthesis → iron overload in the basal ganglia |
| 3. Genetics | Autosomal recessive; PANK2 gene at 20p13-p12.3; more than 200 pathogenic variants reported |
| 4. General epidemiology | Prevalence about 1–3 per 100,000 (all NBIA); PKAN accounts for about 50% of NBIA |
| 5. Pathophysiology | Impaired CoA synthesis → excess cysteine accumulation → iron chelation → iron deposition in the globus pallidus → oxidative stress → neuronal death |
| 6. Symptoms | Gait disturbance, dystonia, extrapyramidal symptoms, cognitive decline, retinal degeneration |
| 7. Signs | Generalized dystonia, extrapyramidal rigidity, dysarthria, in some cases pigmentary retinal degeneration |
| 8. Screening | Genetic testing based on family history; in dystonia with childhood onset, check brain MRI for the eye-of-the-tiger sign |
| 9. Diagnosis | Brain MRI T2 "eye-of-the-tiger sign," PANK2 gene sequencing (confirmatory) |
| 10. Treatment | Iron chelation (deferiprone clinical studies), deep brain stimulation (DBS), symptomatic treatment of dystonia |
| 11. Prognosis | Classic form: loss of ambulation within 10–15 years, early death; atypical form: relatively mild, survival into adulthood |
| 12. Prevention | Genetic counseling, carrier testing, prenatal diagnosis, PGT-M |
| 13. References | Zhou B et al. Nat Genet 2001 and 9 other papers |
Hallervorden-Spatz disease was named in 1922, when the German neurologist Julius Hallervorden and neuropathologist Hugo Spatz described a case of 5 siblings with deposition of brown pigment (iron pigment) in the basal ganglia, especially the globus pallidus and substantia nigra pars reticulata. The disease subsequently drew attention as a cause of progressive extrapyramidal movement disorders with childhood onset. With the introduction of brain MRI in the late 20th century, the characteristic "eye-of-the-tiger sign" in the globus pallidus on T2-weighted images was established as the imaging marker for diagnosis. In 2001, Zhou et al. discovered that mutations in the PANK2 (pantothenate kinase 2) gene cause the disease, and its name was changed to pantothenate kinase-associated neurodegeneration (PKAN). It was the first type with an established molecular diagnosis within the broader category of neurodegeneration with brain iron accumulation (NBIA). Meanwhile, because of the historical fact that Hallervorden was unethically involved in collecting brain tissue during the Nazi era, the academic community has increasingly adopted the name PKAN. In addition to PKAN, various NBIA subtypes have now been identified, including MPAN (mitochondrial membrane protein-associated), BPAN (beta-propeller protein-associated), and COASY protein-associated.
The direct cause of PKAN is functional deficiency of the pantothenate kinase 2 enzyme due to mutations in the PANK2 (pantothenate kinase 2) gene. Pantothenate kinase 2 catalyzes the first reaction, phosphorylating pantothenic acid (vitamin B5) to produce 4'-phosphopantothenate, which is the rate-limiting step of coenzyme A (CoA) biosynthesis. Through its mitochondrial targeting sequence, PANK2 localizes to the inner mitochondrial membrane and is highly expressed, particularly in the basal ganglia of the brain. When PANK2 function is lost, CoA synthesis decreases and its precursors, cysteine and phosphopantothenate, accumulate excessively. The excess cysteine acts as a potent iron chelator, sequestering intracellular iron ions, and reactive oxygen species (ROS) are generated through the Fenton reaction at sites where iron-cysteine complexes form. This oxidative stress selectively damages neurons and glial cells of the globus pallidus and substantia nigra. CoA deficiency also disrupts various cellular metabolic pathways, including fatty acid metabolism, the TCA cycle, and acetylation reactions, resulting in impaired energy metabolism. More than 200 PANK2 mutations have been reported, including missense, nonsense, frameshift, and splice-site variants.
PKAN follows an autosomal recessive mode of inheritance. The causative gene PANK2 is located on the short arm of chromosome 20 (20p13-p12.3) and consists of 7 exons. The risk of disease in the children of an affected couple is 25%. PANK2 mutations have been reported in diverse ethnic groups worldwide, and no clustering in particular ethnic groups is known. Some genotype-phenotype correlation exists: missense mutations are generally associated with the atypical form (later onset, milder), whereas loss-of-function mutations (truncating mutations) tend to be associated with the classic form (early onset, severe). However, even the same mutation can produce different clinical phenotypes, so genotype alone cannot fully predict an individual patient's prognosis. In NBIA patients without an identified PANK2 mutation (with the eye-of-the-tiger sign), the possibility of an NBIA subtype other than PKAN (MPAN: C19orf12, BPAN: WDR45, COASY: COASY gene, etc.) should be considered. The carrier frequency is estimated at about 1/100–1/200, but accurate population data are limited. Genetic diagnosis is made by Sanger sequencing or an NGS-based neurodegeneration gene panel.
The prevalence of NBIA (neurodegeneration with brain iron accumulation) as a whole is estimated at about 1–3 per 100,000. PKAN is the most common form of NBIA, accounting for about 35–50% of all NBIA. The estimated prevalence of PKAN is therefore about 0.5–1.5 per 100,000. About 1,000–2,000 patients have been reported worldwide, but because diagnosis is difficult and often delayed, the actual number of patients is thought to be higher. Epidemiological data from Asia, including Korea, are limited. There is no sex difference, and it occurs in all ethnic groups. Onset of classic PKAN is mostly before age 10 (mean 3–4 years), whereas the atypical form begins at 13–14 years or in adulthood. The classic form accounts for about 75% of cases. The average delay to diagnosis is several years or more, and it is important to consider PKAN quickly in the differential diagnosis of pediatric dystonia. International patient organizations such as NBIA Europe and the NBIA Alliance are leading epidemiological data collection and clinical research.
The core of the pathophysiology of PKAN is impaired CoA synthesis due to PANK2 enzyme deficiency, together with iron deposition and oxidative stress in the basal ganglia. CoA is a coenzyme essential for hundreds of cellular metabolic reactions, including fatty acid oxidation, the TCA cycle, acetylcholine synthesis, and histone acetylation. When PANK2 function is lost, the biosynthetic pathway from pantothenic acid to CoA is blocked, and the precursor metabolite 4'-phosphopantothenate and cysteamine by-products, especially cysteine, accumulate. Cysteine and its derivatives are potent iron chelators that bind strongly to intracellular iron ions. The globus pallidus and substantia nigra pars reticulata have higher iron content than other brain regions and are particularly vulnerable to PANK2 deficiency. In iron-cysteine complexes, hydroxyl radicals are generated through the Fenton reaction (Fe2+ + H2O2 → Fe3+ + OH- + OH·), causing oxidative damage to lipids, proteins, and DNA. This oxidative stress activates mitochondrial dysfunction, endoplasmic reticulum stress, and apoptotic pathways, ultimately leading to selective death of basal ganglia neurons and glial cells. In addition, impaired fatty acid metabolism due to CoA deficiency alters membrane phospholipid composition, reducing neuronal membrane stability. This combined mechanism explains the characteristic signal changes in the globus pallidus seen on MRI.
The clinical symptoms of PKAN are divided into classic and atypical forms. Classic PKAN begins at 3–10 years of age and progresses rapidly. The most prominent early symptom is gait disturbance, with abnormal gait patterns such as toe-walking or inward turning of the ankles. This results from dystonia of the lower limbs and progresses to generalized dystonia over the course of the disease. Muscle rigidity, dysarthria (progressive slurring of speech), and dysphagia accompany it, and in the late stage the limb muscles assume fixed postures (flexion or extension). Retinal degeneration (retinitis pigmentosa) develops in about 2/3 of patients with the classic form, causing decreased vision and night blindness. Cognitive function is relatively preserved early on but may decline as the disease progresses. Psychiatric and behavioral abnormalities (impulsivity, aggression, depression) may also occur. Atypical PKAN begins after age 13 and progresses slowly. Speech disorders (dysarthria, fluency disorders), psychosis (psychotic symptoms), and behavioral changes are prominent early symptoms, and dystonia may develop later or be mild. Parkinsonian features (rigidity, bradykinesia) may also occur.
On physical examination, the key findings in PKAN are abnormalities of the extrapyramidal system. Dystonia is the most prominent motor sign, with abnormal postures and twisting movements caused by sustained, repetitive muscle contractions. It is initially confined to the limbs (especially the legs) but, with progression, spreads to become generalized, involving the trunk, neck, and face. Extrapyramidal rigidity takes the form of lead-pipe rigidity, with constant resistance felt during passive limb movement. Dysarthria results from dystonic involvement of the orofacial muscles, making speech slurred or slow. Impaired swallowing reflexes and abnormal swallowing function are also identified on examination. In addition to extrapyramidal rigidity, upper motor neuron signs (hyperreflexia, positive Babinski sign) may be present, because the corticospinal tract is affected by the basal ganglia lesions. When retinitis pigmentosa is present, visual field constriction, night blindness, and decreased vision are identified on ophthalmologic examination. Psychiatric evaluation may reveal impulse control disorders, poor concentration, and behavioral abnormalities. Eye movements are generally preserved, but supranuclear gaze palsy may occur in some patients.
Population screening for PKAN is not currently performed. The clinically important screening approach is to suspect PKAN early in patients who develop progressive dystonia in childhood and to proceed with diagnostic testing. Typical situations for applying screening are: (1) children with progressive generalized dystonia beginning before age 10, (2) a combination of gait disturbance and dysarthria in childhood, (3) progressive dystonia accompanied by retinal degeneration, (4) children with a family history (a similar disease in siblings or cousins). In these cases, brain MRI (T2-weighted images) is performed immediately to look for the "eye-of-the-tiger sign" in the globus pallidus, and PANK2 gene sequencing is ordered at the same time. When a new pregnancy occurs in a family with a PKAN diagnosis, the PANK2 variant status of the fetus can be determined by prenatal genetic diagnosis (amniocentesis or chorionic villus sampling). For carrier couples, PGT-M (preimplantation genetic testing) is also an option. NBIA-related multigene panel testing is used in a stepwise diagnostic approach to differentiate the various NBIA subtypes.
PKAN is diagnosed by the combination of characteristic MRI findings and genetic testing. Brain MRI is the most important diagnostic tool, and the "eye-of-the-tiger sign" on T2-weighted imaging (T2WI) or T2* GRE imaging is the classic imaging marker of PKAN. This finding appears in the globus pallidus as a central area of T2 hyperintensity (neuronal loss and reactive gliosis in the medial globus pallidus) surrounded by an area of T2 hypointensity (iron deposition), and it is named for its resemblance to a tiger's eye. The sign is not specific to PKAN (it can occasionally appear in other NBIA subtypes) but is observed in more than about 90% of PKAN patients. Confirmation is by PANK2 gene sequencing, with the diagnosis confirmed when pathogenic variants are identified on both alleles. Exon deletion/duplication analysis by MLPA is also performed together with sequencing to increase diagnostic sensitivity. If the eye-of-the-tiger sign is present but no PANK2 variant is found, panel testing including the genes for other NBIA subtypes (C19orf12, WDR45, COASY, FA2H, ATP13A2, etc.) is performed. Ophthalmologic examination (electroretinography, fundus photography) checks for retinitis pigmentosa, and electrophysiological testing and neuropsychological assessment are also added.
There is currently no approved disease-modifying therapy for PKAN. The main treatment attempt based on pathophysiology is iron chelation therapy. The iron chelator deferiprone reduced iron deposition in the globus pallidus and stabilized symptoms in some patients in small clinical studies, but a large 2023 randomized clinical trial (TIRCON) did not show statistically significant clinical improvement. Coenzyme A precursor supplementation (pantothenic acid supplementation) also has a theoretical basis, but its clinical effect is minimal. Phosphopantothenate (4'-PP) supplementation has shown effects in animal models and is in clinical trials. Symptomatic treatment is currently the core of therapy: for dystonia control, trihexyphenidyl (an anticholinergic), clonazepam, baclofen (oral or intrathecal), botulinum toxin injection (for focal dystonia), and tetrabenazine (a dopamine-depleting agent) are used. Deep brain stimulation (DBS) of the internal globus pallidus (GPi) has been reported to be effective in patients with drug-refractory dystonia, and a case of asymmetric bilateral DBS was also published in 2024. Rehabilitation (physical, occupational, and speech therapy), assistive devices, nutritional management, ophthalmologic follow-up (management of retinal degeneration), and psychiatric support make up multidisciplinary supportive care.
The prognosis of PKAN differs markedly between the classic and atypical forms. The classic form progresses rapidly, and most patients lose the ability to walk and become wheelchair-dependent within 10–15 years of onset. Respiratory muscle involvement, aspiration pneumonia, and malnutrition occur as late complications, and death often occurs in the teens to twenties. The atypical form progresses slowly, and patients may survive into adulthood, sometimes into their 40s–50s, but functional decline continues with the cumulative progression of dystonia. Severe cognitive decline greatly affects quality of life. When retinal degeneration is present, vision loss causes additional functional impairment. Deep brain stimulation (DBS) has some effect on dystonia control and may prolong the period of preserved function in some patients. To date, treatment is limited in fundamentally changing the natural course of the disease, so optimal multidisciplinary supportive care and prevention of complications are decisive for survival and maintaining quality of life. Clinical natural history research databases for PKAN are being built internationally.
Because PKAN is an autosomal recessive genetic disease, when both parents are carriers of a pathogenic PANK2 variant, the risk of disease in each child is 25%. The main method to prevent this is preimplantation genetic testing (PGT-M). After in vitro fertilization, the PANK2 genotype of embryos is analyzed and healthy embryos without biallelic variants are selected for transfer, preventing the birth of an affected child. During pregnancy, the fetal genotype can be determined by amniocentesis (15–20 weeks of gestation) or chorionic villus sampling (10–13 weeks of gestation). Genetic counseling should be offered to the family, including siblings and parents of PKAN patients, with carrier testing and counseling on recurrence risk. In terms of secondary prevention, early diagnosis when dystonia begins, prompt initiation of drug treatment for dystonia, and timely evaluation of indications for DBS are important for preserving function. Complications are minimized through regular ophthalmologic follow-up for retinal degeneration and management of nutritional status (preventing malnutrition and aspiration). There is currently no established dietary or pharmacological intervention that can prevent iron deposition, but high-dose antioxidant (vitamin E, etc.) supplementation is being tried in some patients to reduce oxidative stress.